Related Experiment Video
Updated: Jun 6, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Why we are not able to find the coronary heart disease gene - apoE as an example
R Poledne1, J A Hubáček, V Staněk
1Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. rudolf.poledne@ikem.cz
Insights
Apolipoprotein E gene variants increase acute coronary syndrome risk, especially when traditional cardiovascular factors like smoking, diabetes, and hypertension are absent. This highlights gene-environment interactions in heart disease development.
Area of Science:
- Cardiovascular Genetics
- Atherosclerosis Research
- Population Health Studies
Background:
- The apolipoprotein E (APOE) gene is a key candidate gene for cardiovascular diseases.
- Understanding APOE gene polymorphism's role in acute coronary syndrome (ACS) is crucial for risk stratification.
- The influence of traditional cardiovascular risk factors on this association requires further investigation.
Purpose of the Study:
- To investigate the association between apolipoprotein E gene polymorphism and acute coronary syndrome (ACS).
- To determine if traditional cardiovascular risk factors modulate the relationship between APOE genotype and ACS manifestation.
- To assess the impact of combined risk factors on ACS risk in a high-risk Czech population.
Main Methods:
- Case-control study involving 1066 ACS patients and 1066 age-matched controls from Prague.
- Genotyping for apolipoprotein E gene polymorphism.
- Statistical analysis to compare genotype frequencies and calculate odds ratios, stratified by cardiovascular risk factors (smoking, diabetes, hypertension).
Main Results:
- The disadvantageous E4+ genotype was significantly more frequent in ACS patients (22.38%) compared to controls (16.76%) (P < 0.01).
- Odds ratios for ACS associated with the E4+ genotype increased progressively when patients were free of traditional risk factors: 1.35 (all), 1.48 (non-smokers), 1.53 (non-smokers + non-diabetics), and 1.71 (non-smokers + non-diabetics + normotensives).
- The effect of APOE genotype on ACS risk is non-uniform and significantly modified by the presence or absence of cardiovascular risk factors.
Conclusions:
- The apolipoprotein E genotype is associated with an increased risk of acute coronary syndrome in the studied Czech population.
- Traditional cardiovascular risk factors, such as smoking, diabetes, and hypertension, significantly modify the impact of APOE gene polymorphism on ACS risk.
- This suggests a complex interplay between genetic predisposition and environmental factors in the pathogenesis of atherosclerosis and ACS.
Abstract:
The apoprotein E gene ranks among the most discussed candidate genes for cardiovascular disease. We studied whether the association between apoprotein E gene polymorphism and manifestation of acute coronary syndrome is modulated by the presence/absence of traditional cardiovascular risk factors. The population under study were 1066 patients (men under 65 years) admitted between 2006- 2009 to five coronary care units in Prague (GENetic DEtermination of Myocardial Infarction in Prague) and the control population (1066 age-matched men selected from the Czech population sample). The frequency of disadvantage genotype E4+ was significantly higher (P < 0.01) in acute coronary syndrome patients (22.38 %) than in controls (16.76 %). When the acute coronary syndrome group was step by step limited to non-smokers, non-diabetics and normotensive individuals, the odds ratio displayed a gradual increase from 1.35 (for the entire group) through 1.48 (non-smokers), 1.53 (non-smokers+non-diabetics) to 1.71 (non-smokers+non-diabetics+normotensives). The effect of the apoprotein E gene on the individual risk of acute coronary syndrome is nonhomogenous within the patient groups. This association of apoprotein E gene with acute coronary syndrome is strongly modified by the presence/absence of traditional cardiovascular factors of atherosclerosis in a high-risk Czech population.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Coronary Artery Disease I: Introduction
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Coronary Artery Disease II: Pathophysiology
Genetic Lingo
